Jay Yang, MD, Oncology, Detroit, MI, Karmanos Cancer Center

JayYangMD

Oncology Detroit, MI

Hematologic Oncology

Associate Professor, Karmanos Cancer Institute, Wayne State University SOM

Overview of Dr. Yang

Dr. Jay Yang is an oncologist in Detroit, MI and is affiliated with multiple hospitals in the area, including Karmanos Cancer Center, DMC Harper University Hospital, and DMC - Detroit Receiving Hospital. He received his medical degree from University of Michigan Medical School and has been in practice 19 years. Dr. Yang accepts several types of health insurance, listed below. He is one of 73 doctors at Karmanos Cancer Center and one of 43 doctors at DMC Harper University Hospital who specialize in Oncology.

Education & Training

  • Providence Hospital and Medical Centers
    Providence Hospital and Medical CentersFellowship, Hematology/Oncology, 2008 - 2011
  • Providence Hospital and Medical Centers
    Providence Hospital and Medical CentersResidency, Internal Medicine, 2005 - 2008
  • Providence Hospital and Medical Centers
    Providence Hospital and Medical CentersInternship, Transitional Year, 2004 - 2005
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1998

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2007 - 2023
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
    Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
    Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...
    Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    PriorityHealth HMO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment